Articles
27-Aug-2010
Although around 2 million people died as a result of tuberculosis (TB) in 2002 international efforts to tackle its spread are being hampered by complacency and underinvestment.
Uneven global impact Although around 2 million people died as a result of tuberculosis (TB) in 2002, figures from the World Health Organization (WHO) on TB incidence and mortality reveal the contrast in how it affects industrialised and developing regions. For example, in 2002, Europe accounted for 4% of global deaths associated with TB, but in Africa the corresponding figure was just over 30% and in South-East Asia it was 34% (1). The dangers of complacency This ‘uneven impact’ that TB has around the world has meant that it has often slipped from being a major healthcare priority in industrialised countries - and…
Uneven global impact Although around 2 million people died as a result of tuberculosis (TB) in 2002, figures from the World Health Organization (WHO) on TB incidence and mortality reveal the contrast in how it affects industrialised and developing regions. For example, in 2002, Europe accounted for 4% of global deaths associated with TB, but in Africa the corresponding figure was just over 30% and in South-East Asia it was 34% (1). The dangers of complacency This ‘uneven impact’ that TB has around the world has meant that it has often slipped from being a major healthcare priority in industrialised countries - and…
27-Aug-2010
Bacterial skin diseases like gangrene can now expect an onslaught of new specialist medications. However, skin infections make up a relatively small proportion of the $20.4 billion annual global antibacterial market, which, says Datamonitor's Amber Gibson, raises questions about why such conditions are the current focus of so much antibacterial product development...
Although skin and skin structure infections represent one of the most common types of bacterial ailments, they are still relatively infrequent when compared to respiratory tract and urinary tract infections. Skin and skin structure infections accounted for only 3% of the $6.5 billion US drugstore sales attributable to antibacterial infections in 2003. However, skin infections are the one sector of the anti-bacterial market wher…
Although skin and skin structure infections represent one of the most common types of bacterial ailments, they are still relatively infrequent when compared to respiratory tract and urinary tract infections. Skin and skin structure infections accounted for only 3% of the $6.5 billion US drugstore sales attributable to antibacterial infections in 2003. However, skin infections are the one sector of the anti-bacterial market wher…
By 2012, the anti-obesity drugs market will be worth an estimated $2.5 billion globally, compared to $526 million today. However, new drugs will not be the answer to the growing obesity problem. Datamonitor's Jasjeet Mohain argues that increasing education and awareness of the importance of good diet and exercise will remain crucial to combating obesity...
Datamonitor estimates that there are 127 million obese people in the , , , , , and the and over half of them reside in the . Despite increasing health awareness campaigns and attempts to slow down the startling increase in obesity rates, Datamonitor predicts that the prevalence of obesity will increase to 168 million in the alone by 2012. Health complications and comorbidities associated with obesity are a huge drain on national heal…
Datamonitor estimates that there are 127 million obese people in the , , , , , and the and over half of them reside in the . Despite increasing health awareness campaigns and attempts to slow down the startling increase in obesity rates, Datamonitor predicts that the prevalence of obesity will increase to 168 million in the alone by 2012. Health complications and comorbidities associated with obesity are a huge drain on national heal…
New clinical research presented at the 15th International AIDS Conference (IAC) shows that Fuzeon is proving to be remarkably effective in the first long-term trial of its benefits.
However, its administration by subcutaneous injection is precluding therapy in up to 80% of patients. Datamonitor's Laura Harris looks at some later line therapies that could be orally available, prompting greater uptake... Fuzeon (enfuvirtide) was developed by Roche and Trimeris and launched in the in March 2003, with European launches taking place throughout 2003 and 2004. It was licensed as a salvage therapy in patients who have demonstrated virologic failure to alternative antiretroviral (ARV) treatment and have developed resistant strains of HIV. Fuzeon is the first novel HIV drug to reach the market for…
However, its administration by subcutaneous injection is precluding therapy in up to 80% of patients. Datamonitor's Laura Harris looks at some later line therapies that could be orally available, prompting greater uptake... Fuzeon (enfuvirtide) was developed by Roche and Trimeris and launched in the in March 2003, with European launches taking place throughout 2003 and 2004. It was licensed as a salvage therapy in patients who have demonstrated virologic failure to alternative antiretroviral (ARV) treatment and have developed resistant strains of HIV. Fuzeon is the first novel HIV drug to reach the market for…
What exactly is a Curriculum Vitae? Is it a List of your Skills and Experience? Is it a Mini Biography? Is it a chance to get someone to fully appreciate your Skills and Achievements?
Truth be known, It’s none of these.
What is a CV? A CV in its purest form is nothing more and nothing less than a chance to market yourself to prospective recruiters and employers to increase your chances of being invited to an interview. A CV is an Interview-Winning Tool. It is not a Personal Biography, or a List of your skills and experience, it is a fluid document which means different things to different people, but is relevant to all. CV Myths Before looking at what makes a good CV, lets first dispel a few myths: ‘The more they know about me, the more chance they have of being impressed’ Wrong…
What is a CV? A CV in its purest form is nothing more and nothing less than a chance to market yourself to prospective recruiters and employers to increase your chances of being invited to an interview. A CV is an Interview-Winning Tool. It is not a Personal Biography, or a List of your skills and experience, it is a fluid document which means different things to different people, but is relevant to all. CV Myths Before looking at what makes a good CV, lets first dispel a few myths: ‘The more they know about me, the more chance they have of being impressed’ Wrong…
Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within the central nervous system.
DailyUpdates 13th July: Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within the central nervous system. It has been estimated that 9% of the population suffers from moderate to severe n…
DailyUpdates 13th July: Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within the central nervous system. It has been estimated that 9% of the population suffers from moderate to severe n…
Recently published data from the GENOA study has demonstrated that dyslipidemia is highly prevalent in hypertensive adults and that this condition is insufficiently treated in more than half of the cases. As Datamonitor's Laurent Chanroux explains, the results lend further support to cross risk-factor, single pill combination therapies such as Pfizer's Caduet...
Less than one third of hypertensive adults with dyslipidemia are drug-treated, according to findings from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. In addition, the research also showed that fewer than half of those treated achieve recommended lipid levels. This suggests a need for a more aggressive treatment of dyslipidemic hypertensives and highlights the potential of cross risk-factor single-pill combination…
Less than one third of hypertensive adults with dyslipidemia are drug-treated, according to findings from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. In addition, the research also showed that fewer than half of those treated achieve recommended lipid levels. This suggests a need for a more aggressive treatment of dyslipidemic hypertensives and highlights the potential of cross risk-factor single-pill combination…
Analysts have recently predicted that the market for airway inflammatory diseases will increase by 35% to over $18 billion by 2011. A recent target evaluation report produced for the drug development sector concluded that the TH2-derived cytokines IL-4, and more so IL-13 represent promising targets. Both cytokines activate IL-4Ralpha to produce multiple functional changes observed in asthma patients. A recent report published in the Journal of Immunology elucidates the divergent mechanisms th
The emerging role of the IL-4/IL-3 cytokine receptor IL-4Ralpha in asthma DailyUpdates 9th July: Analysts have recently predicted that the market for airway inflammatory diseases will increase by 35% to over $18 billion by 2011. A recent target evaluation report produced for the drug deve…
The emerging role of the IL-4/IL-3 cytokine receptor IL-4Ralpha in asthma DailyUpdates 9th July: Analysts have recently predicted that the market for airway inflammatory diseases will increase by 35% to over $18 billion by 2011. A recent target evaluation report produced for the drug deve…
27-Aug-2010
Metabolic syndrome, a cluster of common metabolic disorders including obesity, pre-diabetes, abnormal lipid levels and high blood pressure, is now approaching epidemic proportions worldwide.
A new report* from independent market analyst Datamonitor (DTM.L) reveals that a total 115 million individuals suffer from this syndrome in the US, Japan, France, Germany, Italy, Spain and the UK. According to Datamonitor, this number is set to increase rapidly, fuelled by the rising obesity and diabetes epidemic. Significant though it is, the metabolic syndrome patient population remains poorly diagnosed and there are no drugs currently available to treat all components of metabolic syndrome. Lifestyle changes are recommended as first line therapy, however the proposed lifestyle counseling…
A new report* from independent market analyst Datamonitor (DTM.L) reveals that a total 115 million individuals suffer from this syndrome in the US, Japan, France, Germany, Italy, Spain and the UK. According to Datamonitor, this number is set to increase rapidly, fuelled by the rising obesity and diabetes epidemic. Significant though it is, the metabolic syndrome patient population remains poorly diagnosed and there are no drugs currently available to treat all components of metabolic syndrome. Lifestyle changes are recommended as first line therapy, however the proposed lifestyle counseling…
SureScripts, in partnership with the Massachusetts Medical Society, is launching an educational network providing physicians with information from the early adopters of ePrescribing technology. Datamonitor's Kimberly O'Malley argues that educational forums like this allow members to more efficiently evaluate and subsequently adopt electronic prescribing as a solution for their practices...
SureScripts is the largest of several technology vendors that have developed a solution to improve the quality, safety, and efficiency of the prescribing process by establishing an electronic prescribing network between physicians and pharmacists. SureScripts activates its electronic prescribing network (called SureScripts Messenger Services) in individual states using a consolidated community-wide effo…
SureScripts is the largest of several technology vendors that have developed a solution to improve the quality, safety, and efficiency of the prescribing process by establishing an electronic prescribing network between physicians and pharmacists. SureScripts activates its electronic prescribing network (called SureScripts Messenger Services) in individual states using a consolidated community-wide effo…
Post-Conference Workshop:
Structuring the Deal--
Contract Development and Negotiations for Improved Results
Gain Valuable Information to: Reduce the attrition rate and increase your speed-to-market through improved collaborative relations Bring higher quality results into your projects through proper partnering techniques Develop a plan to identify and evaluate discovery partners Acquire new negotiation tactics to strengthen your contracts Improve provider performance with proven metric strategies Reduce time gaps due to miscommunication/misinformation Drive discovery to bring your company out on top!
Gain Valuable Information to: Reduce the attrition rate and increase your speed-to-market through improved collaborative relations Bring higher quality results into your projects through proper partnering techniques Develop a plan to identify and evaluate discovery partners Acquire new negotiation tactics to strengthen your contracts Improve provider performance with proven metric strategies Reduce time gaps due to miscommunication/misinformation Drive discovery to bring your company out on top!
27-Aug-2010
This edition of "Emerging Drug Discovery Targets" features new approaches to improving intestinal uptake of poorly absorbed therapeutics; a dual 5-LO inhibitor/H1 receptor antagonist for the treatment of asthma; Sitaxentan as an effective treatment of pulmonary arterial hypertension; Kv1.3 potassium channel blockade as an approach to insulin resistance; Drug delivery technology predicted to allow safer and more effective use of steroids in the treatment of rheumatoid arthritis; VEGF receptor tyr
Emerging Drug Discovery Targets from to view this alert on line please go to http://www.leaddiscovery.co.uk/TherapeuticAdvances%20Archive/June%2028th%20emerging%20targets.htm ************************************** "Emerging Drug Discovery Targets" provides a regular summary of some of the most exc…
Emerging Drug Discovery Targets from to view this alert on line please go to http://www.leaddiscovery.co.uk/TherapeuticAdvances%20Archive/June%2028th%20emerging%20targets.htm ************************************** "Emerging Drug Discovery Targets" provides a regular summary of some of the most exc…
Rheumatoid arthritis is one of the more common autoimmune diseases. LeadDiscovery’s recent state of the art evaluation of rheumatoid arthritis therapeutics evaluates advances in our understanding of the etiology of the disease. One field of research extensively analyzed in this report is angiogenesis. Inhibitors of receptor tyrosine kinase with specific activity against the VEGFRs have been developed in an attempt to prevent angiogenesis. One such molecule is PTK787/ZK222584, synthesized and dev
Rheumatoid arthritis (RA) is one of the more common autoimmune diseases affecting approximately 5 million individuals in the Western world. As described in LeadDiscovery’s state of the art evaluation of rheumatoid arthritis therapeutics (click here), this field is attracting massive interest in the…
Rheumatoid arthritis (RA) is one of the more common autoimmune diseases affecting approximately 5 million individuals in the Western world. As described in LeadDiscovery’s state of the art evaluation of rheumatoid arthritis therapeutics (click here), this field is attracting massive interest in the…
27-Aug-2010
‘To change Career, or to change Company?’ Although these seven words are easy to utter (and utter you will, over and over again), they are actually very deceptive as really what you are asking is, ‘Which direction should my life now take?’
Consider these statements: 1. I enjoy what I’m doing at the moment, but I often wonder if I would be better suited to something else 2. Although I have a good Idea of what I want to achieve, I have no motivation to get there. 3. I’ve worked at this company for a long time, and am very comfortable, but I’m not sure what else there is for me to do here. If you recognise any of these statements then it is highly likely you have reached the ‘Career Crossroads’. Although it sounds like a kind of Career Mid-life crisis it really isn’…
Consider these statements: 1. I enjoy what I’m doing at the moment, but I often wonder if I would be better suited to something else 2. Although I have a good Idea of what I want to achieve, I have no motivation to get there. 3. I’ve worked at this company for a long time, and am very comfortable, but I’m not sure what else there is for me to do here. If you recognise any of these statements then it is highly likely you have reached the ‘Career Crossroads’. Although it sounds like a kind of Career Mid-life crisis it really isn’…
An estimated 5 million individuals suffer from rheumatoid arthritis. Corticosteroids are the most dramatically effective short-term anti-inflammatory drugs; however, clinical benefit for rheumatoid arthritis often diminishes with time. Because of their long-term systemic side effects, corticosteroids are usually given only after a careful and prolonged trial of less hazardous drugs. Liposomes are artificial vesicles efficiently phagocytosed by macrophages and recent advances such as the developm
Rheumatoid arthritis is one of the more common autoimmune diseases along with multiple sclerosis, type I diabetes and Crohn’s disease. Approximately one in five people in the western world suffer from autoimmune diseases and some estimates indicate that 75% of these are women. In total it is predict…
Rheumatoid arthritis is one of the more common autoimmune diseases along with multiple sclerosis, type I diabetes and Crohn’s disease. Approximately one in five people in the western world suffer from autoimmune diseases and some estimates indicate that 75% of these are women. In total it is predict…
The R&D activity surrounding novel oral treatments of diabetes is considerable and one particular target that has recently received attention is the Kv1.3 potassium channel. Blocking this channel has been thought to be of value in the treatment of multiple sclerosis and more recently for preventing weight gain. Now researchers from Yale have demonstrated that Kv1.3 channel blockers may also increase insulin sensitivity in genetically obese and diabetic mice
According to WHO, there are some 130 million diagnosed diabetics in the world, a figure that is predicted to increase to 300 million by 2025. The market for diabetes therapeutics is also rising with global sales reportedly topping $8.1 billion for the 12 months to September 2000, a 19% increase over the previous 12 months (for a full ana…
According to WHO, there are some 130 million diagnosed diabetics in the world, a figure that is predicted to increase to 300 million by 2025. The market for diabetes therapeutics is also rising with global sales reportedly topping $8.1 billion for the 12 months to September 2000, a 19% increase over the previous 12 months (for a full ana…
Pulmonary arterial hypertension (PAH) represents an unmet market. Initial breakthroughs in treatment focussed on the rare form of this condition, idiopathic pulmonary arterial hypertension. Recently however a key advance in the treatment of PAH was made with the launch of Actelion's twice-daily Tracleer (bosentan) as the first orally active treatment of both idiopathic and secondary PAH. Tracleer is the first generation of a class of drugs known as endothelin receptor antagonists and blocks two
Pulmonary arterial hypertension (PAH) exists in a rare idiopathic or unexplained form (which occurs in familial and sporadic forms) called idiopathic pulmonary arterial hypertension (IPAH, previously referred to as primary pulmonary hypertension, PPH)) and a relatively common form of secondary pulmo…
Pulmonary arterial hypertension (PAH) exists in a rare idiopathic or unexplained form (which occurs in familial and sporadic forms) called idiopathic pulmonary arterial hypertension (IPAH, previously referred to as primary pulmonary hypertension, PPH)) and a relatively common form of secondary pulmo…
27-Aug-2010
Everyone knows that first impressions count. There have been countless articles on how to ‘Dress to impress’, and how to make sure the first five minutes of your interview are geared towards creating the perfect ‘First Impression’.
Everyone knows that first impressions count. There have been countless articles on how to ‘Dress to impress’, and how to make sure the first five minutes of your interview are geared towards creating the perfect ‘First Impression’. But what about last impressions? Is saying goodbye less important that saying hello? When the interview is over, and you jump up from you chair declaring that you’re ‘Glad that’s over, as I’m desperate to head off down the pub to catch the game’, or ‘I’m happy the interview is finished as I’ve had loads of interviews this week, and…
Everyone knows that first impressions count. There have been countless articles on how to ‘Dress to impress’, and how to make sure the first five minutes of your interview are geared towards creating the perfect ‘First Impression’. But what about last impressions? Is saying goodbye less important that saying hello? When the interview is over, and you jump up from you chair declaring that you’re ‘Glad that’s over, as I’m desperate to head off down the pub to catch the game’, or ‘I’m happy the interview is finished as I’ve had loads of interviews this week, and…
Numerous inflammatory mediators have been implicated in the etiology of asthma. Blocking specific inflammatory mediators has frequently yielded unimpressive clinical results and instead the simultaneous targeting or more than one mediator may be of greater use. In the current edition of LeadDiscovery's TherapeuticAdvances work by researchers at UCB who have developed a dual 5-LO inhibitor/H1 receptor antagonist is highlighted
The incidence of asthma has dramatically increased over recent years and although currently available treatments are generally effective, patient compliance is currently poor, especially with respect to inhaled treatment. Furthermore, 5% of patients are unresponsive to these treatments and it is this cohort that accounts for a large segment of asthma related healthcare…
The incidence of asthma has dramatically increased over recent years and although currently available treatments are generally effective, patient compliance is currently poor, especially with respect to inhaled treatment. Furthermore, 5% of patients are unresponsive to these treatments and it is this cohort that accounts for a large segment of asthma related healthcare…
PABORD is the first exhibition and conference dedicated to Outsourcing in Research and Development for the Pharmaceutical and Biotechnology industries.
PABORD is the first exhibition and conference dedicated to Outsourcing in Research and Development for the Pharmaceutical and Biotechnology industries. With an international line-up of renowned speakers, thiscutting-edge new event is taking place at London's ExCel conference and exhibition venue on September 28th and 29th 2004. Almost 200 companies will be participating at PABORD, Europe's first show that focuses completely on the rapidly expanding trend towards outsourcing in the research and development of new therapeutics. PABORD is extremely well timed, considering how this new trend is having such an increasinglyprofound effect on the…
PABORD is the first exhibition and conference dedicated to Outsourcing in Research and Development for the Pharmaceutical and Biotechnology industries. With an international line-up of renowned speakers, thiscutting-edge new event is taking place at London's ExCel conference and exhibition venue on September 28th and 29th 2004. Almost 200 companies will be participating at PABORD, Europe's first show that focuses completely on the rapidly expanding trend towards outsourcing in the research and development of new therapeutics. PABORD is extremely well timed, considering how this new trend is having such an increasinglyprofound effect on the…
